Study Overview: Combination of FTD/TPI with IRI in Advanced Gastric and Esophagogastric Junction Cancer (aGEC)

Background:In 2L+ aGEC, taxanes +/- ramucirumab or IRI are recommended treatment options. IRI has been tested in multiple single arm and randomized trials in second line (2L)+ aGEC, with reported objective response rates (ORR) in the 15–29% range and...